SUMMARY Rapid counter-immunoelectrophoresis (CIE) and radioimmunoassay (RIA) methods for detecting antibody to hepatitis B core antigen (anti-HBc) were used to screen nearly 8000 blood donors, including 919 prisoners. The prevalence of anti-HBc in prisoner donors (3.4%) was significantly higher than that in other donors (0.7%). The three HBsAg positive donors in the series were all anti-HBc positive and, of the other 73 anti-HBc positive donors, 62 had antibody to HBsAg (anti-HBs).
Antibody to hepatitis B core antigen (anti-HBc) is a sensitive indicator of hepatitis B virus (HBV) infection. ' It develops soon after the surface antigen of hepatitis B (HBsAg) appears and persists, without interruption, through the phases of HBsAg loss and anti-HBs development. Some anti-HBc positive blood donations are infectious, and there have been several reports of post-transfusion hepatitis B due to HBsAg negative but anti-HBc positive blood. 24 The extent of this risk from "anti-HBc only" positive blood is unclear.
Blood donations have not routinely been screened for anti-HBc in spite of the potential infectivity of anti-HBc positive blood. There have been several reasons for this. The antigen has been scarce, lack of funds has precluded an extra screening procedure, and it has been assumed that few anti-HBc positive donations that contain undetectable levels of HBsAg will be identified. Also, it has been shown that, in areas of high HBV prevalence, many transfusable donations will be rejected as a result of Accepted for publication 23 February 1983 anti-HBc screening unless there is additional testing for anti-HBs. 5 To assess the value of screening tests for anti-HBc in an area of low prevalence, the occurrence The results for the panels of control sera confirmed that the anti-HBc test was effective in identifying HBsAg positive specimens. All but two
The value of screening blood donors for antibody to hepatitis B core antigen of the panel of 139 HBsAg positive sera, as well as the HBsAg positive donors, were anti-HBc positive by CIE. The two negative anti-HBc results were on specimens with very low levels of HBsAg. Four other HBsAg weakly positive specimens, in the PHLS special panel, were missed by the CIE test for anti-HBc. When RIA for anti-HBc was applied to the special panel one HBsAg specimen was not clearly identified, though it did partially inhibit 125J_ anti-HBc binding. These results do not justify using anti-HBc testing alone to screen blood donations, but they indicate that it can usually confirm HBsAg positivity in donors. Only blood collected in the incubation period of HBV infection is likely to be HBsAg positive but anti-HBc negative.
As well as identifying more weak HBsAg positive specimens, RIA for anti-HBc proved to be more specific than GTE. It gave negative results for all the 19 donors whose sera produced unconfirmable reactions on initial CIE screening. It gave only three positive reactions, out of 2586 donors tested, that were not corroborated by a positive anti-HBs result. These three may have been false-positive reactions or they may belong in a true "anti-HBc only" category. The eight donor sera that were "anti-HBc only" when tested by CIE may fit into the same category.
Donor blood with this pattern of reactivity has given rise to both type B and non-A, non-B posttransfusion hepatitis. [12] [13] [14] It is therefore undesirable that it should be transfused.
The donations found by us to be anti-HBc positive were dealt with as follows: those known to be HBsAg positive were discarded; those anti-HBs positive were sent for inclusion in pools for the production of HBV immune globulin (HBIG); and those in the "anti-HBc only" category were set aside for possible use in blood product manufacture involving processes that inactivate HBV. In our donor population the prevalence of anti-HBc was low enough for all anti-HBc positive blood to be withheld from transfusion. A striking advantage of the anti-HBc test was its rapidity. Both methods described give a result within two hours, and allow quick confirmation of HBsAg screening results and fast release of urgently required fresh blood and blood constituents. This may be particularly useful in providing for those needing multiple transfusions-for example, renal dialysis and immunosuppressed patients. The maindisadvantage of anti-HBc testing was the high incidence of apparently non-specific reactions. Many results could not be reproduced in the more experienced, reference laboratory. Another drawback at the time of the study was the short supply of antigen, though this obstacle has now been overcome by the cloning of HBV DNA sequences in E coli. . E coliderived HBcAg is suitable for an RIA of the kind used here'6 and may give rise to fewer false-positive reactions.
Other disincentives to anti-HBc screening are the potential loss of transfusable blood, and the cost, both of the test itself and of anti-HBs tests that must be done if anti-HBc positive, HBsAg negative units are to be used. These factors will certainly prevent anti-HBc tests being used by poorly-funded laboratories in areas of high prevalence. Elsewhere the benefits from anti-HBc testing, of confirming HBsAg reactions, of identifying donations suitable for HBIG manufacture and of lessening the risk of post-transfusion hepatitis by excluding "anti-HBc only" blood, ought to be studied. Several authors have argued that an anti-HBc test is not useful in blood donor screening," '2' 1 They cite the small number of cases of post-transfusion hepatitis due to anti-HBc positive units brought to the notice of transfusion centres. However they ignore the larger numbers of sub-clinical infections, with HBV and possibly non-A, non-B hepatitis viruses, that may follow transfusion of anti-HBc positive blood. They also overlook several practical advantages of having an anti-HBc test available in transfusion laboratories. In the form of a rapid, one-step RIA the test is well-suited to screening large batches of sera. With an abundant supply of HBcAg from E coli becoming available, it should be reconsidered as an adjunct to HBsAg screening of blood donors. 
